利妥昔单抗是一种人鼠嵌合型IgG1免疫球蛋白,由鼠源性Fab可变区和人源化Fc恒定区嵌合形成,鼠源性Fab可变区与CD20抗原有高度亲和力,其结合后通过诱导细胞凋亡、诱发补体依赖细胞毒作用及抗体依赖细胞毒作用来杀伤正常和肿瘤性CD20+细胞。利妥昔单抗作为第一个被FDA批准的用于治疗复发或难治性CD20+B细胞低度恶性或滤泡性非霍奇金淋巴瘤(NHL)的药物,其 Rituximab, a human mouse chimeric IgGl immunoglobulin, is formed by chimeric murine Fab variable regions and humanized Fc constant regions that have a high affinity for the CD20 antigen , Which upon combination kill both normal and neoplastic CD20 + cells by inducing apoptosis, inducing complement-dependent cytotoxicity, and antibody-dependent cytotoxicity. Rituximab is the first drug approved by the FDA to treat relapsed or refractory CD20 + B-cell low-grade or follicular Non-Hodgkin’s Lymphoma (NHL)